HR+/HER2- Breast Cancer: Inhibiting the PI3K/AKT/mTOR Pathwa

Dr Vidal expands on use of PI3K/AKT/mTOR pathway inhibitors following frontline progression, focusing on the PI3K inhibitor alpelisib for patients with PIK3CA mutations, as well as capivasertib, an AKT inhibitor in development.

Related Keywords

Aditya Bardia , Gregory Vidal , Komal Jhaveri , , Hr Her2 Breast Cancer , Mutations , Cdk4 6 Inhibitors , Second Line Therapies , Endocrine Therapy , Pet , Endocrine Resistance , Giredestrant , Palbociclib , Akt Inhibitors , Capitello 291 , Maintain Trial , Ember 3 , Imlunestrant , Oral Serds , Abemaciclib , Capivasertib , Pi3k , Alpelisib , Toxicity , Gedatolisib , Viktoria 1 , Fulvestrant , Hyperglycemia ,